1,721,051 research outputs found
Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa
No full textADRENAL SECRETION PRODUCED BY ASPHYXIA
Full text linkAsphyxia produces a marked epinephrin discharge. This fact reported by several authors has been denied by others. Our present observations confirm the existence and give some insight into the cause of this phenomenon.Fil: Houssay, Bernardo Alberto. Universidad de Buenos Aires; ArgentinaFil: Molinelli, E. A.. Universidad de Buenos Aires; ArgentinaUnidad documental simpl
Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa
No full textIntroduction: Hidradenitis suppurativa is a chronic, relapsing, debilitating inflammatory dermatologic disease of the terminal hair follicles at intertriginous sites clinically characterized by painful inflammatory nodules, abscesses, draining sinus tracts, and dermal fibrosis. The management of hidradenitis suppurativa is a challenge and usually consists of both medical and surgical approaches, which must often be combined for best outcome. The introduction of biological therapies, specifically TNFα-inhibitors such as adalimumab, has profoundly changed the therapeutic armamentarium of the disease. Areas covered: The PubMed database was searched using combinations of the following keywords: hidradentis suppurativa, biologic therapy, TNF-α inhibitors, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, adverse effects, pharmacodynamics, pharmacology, adverse events, pharmacokinetics, drug interaction. This article reviews and updates the chemistry, pharmacokinetics, mechanism of action, adverse effects, drug interactions of on-label and off-label use of TNF-α inhibitors in HS. Expert opinion: Biologic agents, particularly adalimumab, exhibit clinical efficacy in patients with hidradenitis suppurativa. Careful patient selection and close monitoring during treatment are mandatory to provide safe and effective use of the TNF-α inhibitor. Familiarity with biologic agents is crucial because these agents could become a consolidated treatment option in the clinician’s therapeutic approaches
Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience.
No full text
Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
No full textSneddon-Wilkinson disease and monoclonal gammopathy of undetermined significance in the elderly: Case report
No full textReview: A safety profile of dalbavancin for onand off-label utilization
No full textIntroduction: Dalbavancin is a bactericidal lipoglycopeptide active against gram-positives. Its use has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Methods: We conducted a narrative review of the literature on the safety profile of dalbavancin. The bibliographic research was carried out on the PubMed database on 6 November 2020 by seeking combinations of the following keywords: Dalbavancin, adverse effects, safety, drug interactions, and skin infections. Results: Five double-blind Phase 3 randomized clinical trials, 2 open-label randomized trials, and 4 retrospective studies were identified. No statistically significant differences were found between dalbavancin and comparators in the incidence of adverse events. Retrospective studies confirm the low incidence of adverse events. Conclusion: Dalbavancin is a therapeutic option that has demonstrated an excellent safety profile, also in relation to the other MRSA therapies available. Its use represents a costeffective solution for the treatment of those patients with ABSSSI who would need hospitalization. One limitation of this study is that most of the available data are from Phase III clinical trials. Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data
No full textbackground: hidradenitis suppurativa (HS) is characterized by periodic worsening of both clinical manifestations and symptoms. the aim of this study was to investigate the role of flare outbreak as a possible predictive factor of response to adalimumab. methods: one hundred fifteen HS patients in treatment with adalimumab, with moderate-severe HS, 3 abscesses and inflammatory-nodules (ANs) from 5 Italian centers were included in this retrospective analysis. the information about gender, ages at onset/baseline, therapeutic delay, family history, body mass index, smoking, comorbidities, phenotypes, body areas, severity indexes at baseline was collected. baseline characteristics, total number and timeline of flares were analyzed by regression and survival analysis with hidradenitis suppurativa clinical response (HiSCR). results: during the observational period, 80.9% of patients developed flares, detecting 252 flares. univariate model identified five factors as-sociated with the absence of response: age (P=0.020), comorbidities (P=0.030), genital-perineal involvement (P=0.004), no response at week 12 (P=0.027), and flares outbreak (P=0.010). Joint analysis of recurrent and terminal events showed a positive correlation between flare recurrence and no response (P<0.001). among the identified variables associated with poor response to the therapy: occurrence of a flare before week 12 was the one with the highest risk of no response (P<0.001). CONCLUSIONS: the analysis of a "dynamic" variable, as flares evaluation together with an appropriate clinical baseline assessment can be a useful approach to predict the middle-long-term response to adalimumab. (cite this article as: caposiena caro RD, chiricozzi a, sechi a, molinelli e, venturini m, candi E, et al. flares as dynamic predictive factor of re-sponse to adalimumab in hidradenitis suppurativa, real-lif
- …
